Share Twitter LinkedIn Facebook Email Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma (MM) treatment for patients.
Teclistamab FDA Approval Biweekly Dosing Multiple Myeloma [3 KOL Interviews] Multiple Myeloma 13 Mins Read